CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on validating genetic markers for bladder cancer to improve patient management. By analyzing tumor tissue and urine from a large patient cohort, it aims to develop a risk score system that can guide clinical decisions and potentially reduce healthcare costs.
Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe.
New genomic methods have allowed identifying new markers with potential clinical application.
However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alterations in tumor tissue and urine, as well as polymorphisms in immune response genes, are very promis…
AARHUS UNIVERSITETSHOSPITAL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Barcelona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Vic Barcelona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Rotterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
